1Department of Critical Care, University of Calgary, Calgary, AB, Canada.
2Department of Medicine, University of Manitoba, Winnipeg, MB, Canada.
3Department of Medicine, University of Toronto, Toronto, ON, Canada.
4Center for Health Evaluation and Division of Critical Care Medicine, St. Paul’s Hospital and University of British Columbia, Vancouver, BC, Canada.
5Department of Intensive Care, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia.
6Department of Medicine, Hackensack University Medical Center, Hackensack, NJ.
7Department of Medicine, Cooper Medical School of Rowan University, Camden, NJ.
* See also p. 2294.
This work was performed at University of Manitoba and University of Calgary.
Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal’s website (http://journals.lww.com/ccmjournal).
Development of the existing database used for this study was supported in the past by unrestricted grants from Lilly, Wyeth, Pfizer, Merck, Astra-Zeneca, Astellas, Manitoba Health Research Council, Manitoba Health Sciences Foundation, and the Deacon Foundation.
Dr. Kumar’s institution received grant support from Astellas, Lilly, Pfizer, Merk, Bayer, GSK, and Roche (unrestricted grants). Dr. Marshall served as board member for Asahi Kasei Pharma America (Data Monitoring Committee Member, ART-123). Dr. Parrillo served as board member for Artisan, Sangart, and Cytosorbents. His institution received grant support from the Salem Foundation. The remaining authors have disclosed that they do not have any potential conflicts of interest.
For information regarding this article, E-mail: agarland@hsc.mb.ca
